The IASLC is on the air – with its first-ever podcast “Lung Cancer Considered.”

Maintenance immunotherapy fails to improve survival in extensive-stage small cell lung cancer (SCLC), according to late-breaking results from the CheckMate 451 study to be presented today at the European Lung Cancer Congress (ELCC) 2019.

Two studies to be reported at ELCC 2019 (1,2) provide new insights on the efficacy and safety of immunotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC), where information has previously been lacking despite being the age group most commonly affected.

Participants from across the world will meet in Geneva at the European Lung Cancer Congress (ELCC 2019), 10-13 April 2019, to learn about and discuss the latest research in the field of lung cancer and other thoracic malignancies.

While non-small cell lung cancer (NSCLC) is the more common form of lung cancer and attracts the lion’s share of the research funding, recent developments in small cell lung cancer may be shifting that slightly.

By any measure, lung cancer patients have it rough. But Maryland resident and special education teacher Montessa Lee has been through a particularly arduous ordeal.